2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…2017 American Transplant Congress
Impact of NODAT on Post-Transplant Survival – An Analysis of UNOS Data.
University Hospital Cleveland Medical Center, Cleveland
Background: New Onset Diabetes After Transplantation (NODAT) is common and may adversely affect long-term patient survival. Impact of NODAT on patient survival in heart transplantation…2017 American Transplant Congress
Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development?
Cedars-Sinai Heart Institute, Los Angeles
Background: Primary graft dysfunction (PGD) may occur in up to 30% of heart transplant recipients and has been associated with increased mortality. The development of…2017 American Transplant Congress
Alemtuzumab Use in a Single Center Pediatric Heart Transplant Cohort.
Purpose: To describe the use and complications of alemtuzumab (AMB), a CD52 monoclonal antibody, in pediatric heart transplant (HT) patients (pt).Methods: Retrospective chart review of…2017 American Transplant Congress
Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation.
University of Louisville, Louisville
Background. This study evaluated the management of immunosuppressive therapy and the incidence of acute heart rejection within 1 year from concomitant heart-kidney transplantation (cHTKx) compared…2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…2017 American Transplant Congress
Exploring Differential Antibody Response to Bortezomib in Heart Transplantation.
Northwestern University, Chicago, IL
Twelve heart transplant candidates (2013-2016) received Bortezomib (BTZ) for desensitization. Differential antibody (Ab) response was observed. BTZ cycles consisted of 4 injections of 1.3 mg/m2;…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Simultaneous Heart and Kidney Transplant vs Heart Transplant: Single Center Review of Candidate Selection and List Management.
Background: Increasing numbers of patients with advanced heart and kidney failure undergo simultaneous heart kidney transplant (SHK). Selection criteria in patients with non-dialysis dependent kidney…2017 American Transplant Congress
Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation.
Cedars-Sinai Heart Institute, Los Angeles
Background: Patients (pts) with end stage heart disease undergoing heart transplantation (HT) may be on amiodarone (AD) for arrhythmias. AD may persist for weeks after…
American Transplant Congress abstracts